Cited by 160Gastrointestinal motility and disordersProbiotics and Fermented FoodsInflammatory Bowel Disease

Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders

Open access
Currò, Diego, Ianiro, Gianluca, Pecere, Silvia, Bibbò, Stefano, Cammarota, Giovanni·2017·British Journal of Pharmacology

Abstract

Functional bowel disorders (FBD), mainly irritable bowel syndrome (IBS) and functional constipation (FC, also called chronic idiopathic constipation), are very common worldwide. Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, although less common, has a strong impact on patients' quality of life, as well as being highly expensive for our healthcare. A definite cure for those disorders is still yet to come. Over the years, several therapeutic approaches complementary or alternative to traditional pharmacological treatments, including probiotics, prebiotics, synbiotics, fibre and herbal medicinal products, have been investigated for the management of both groups of diseases. However, most available studies are biased by several drawbacks, including small samples and poor methodological quality. Probiotics, in particular Saccharomyces boulardii and Lactobacilli (among which Lactobacillus rhamnosus), synbiotics, psyllium, and some herbal medicinal products, primarily peppermint oil, seem to be effective in ameliorating IBS symptoms. Synbiotics and fibre seem to be beneficial in FC patients. The probiotic combination VSL#3 may be effective in inducing remission in patients with mild‐to‐moderate ulcerative colitis, in whom Escherichia coli Nissle 1917 seems to be as effective as mesalamine in maintaining remission. No definite conclusions can be drawn as to the efficacy of fibre and herbal medicinal products in IBD patients due to the low number of studies and the lack of randomized controlled trials that replicate the results obtained in the individual studies conducted so far. Thus, further, well‐designed studies are needed to address the real role of these therapeutic options in the management of both FBD and IBD. Linked Articles: This article is part of a themed section on Principles of Pharmacological Research of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.11/issuetoc

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.13632

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 230 · Cited by 160

Research works printed but not linked: 3

  1. Probiotics and nutraceuticals for IBS, CIC and IBD BJP British Journal of Pharmacology (2017) 174 1426-1449 1445 14765381, 2017, 11, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.13632, Wiley Online Library on [20/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
  2. McFarland LV (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16: 2202-2222.
  3. Probiotics and nutraceuticals for IBS, CIC and IBD BJP British Journal of Pharmacology (2017) 174 1426-1449 1447 14765381, 2017, 11, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.13632, Wiley Online Library on [20/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

Authors
Currò, D., Ianiro, G., Pecere, S., Bibbò, S., & Cammarota, G.
Affiliations
  • Università Cattolica del Sacro Cuore (IT)
  • University of Sassari (IT)
Corresponding author
Currò, Diego
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2016-10-25
Volume
174
Issue
11
Pages
1426-1449
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2529713053
Cited by
160
References
230
Citations by year
2026: 4 · 2025: 9 · 2024: 16 · 2023: 22 · 2022: 18 · 2021: 21 · 2020: 24 · 2019: 12 · 2018: 19 · 2017: 12 · 2016: 3
FWCI
2.59
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
Keywords
probiotics, prebiotics, synbiotics, dietary fiber, herbal medicinal products, functional bowel disorders, irritable bowel syndrome, functional constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, Saccharomyces boulardii, Lactobacillus rhamnosus, VSL#3, Escherichia coli Nissle 1917, peppermint oil, psyllium, nutraceuticals
MeSH terms
Animals, Constipation, Dietary Fiber, Humans, Phytotherapy, Quality of Life, Inflammatory Bowel Diseases, Dietary Supplements, Probiotics, Plant Preparations, Irritable Bowel Syndrome, Prebiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review